New treatments to stop kidney damage from diabetes
New siRNA therapeutics to halt diabetic kidney disease
This study is looking at new ways to protect your kidneys from damage caused by diabetes by using tiny particles to deliver special treatments that can help reduce inflammation, and they hope this will lead to better options for people with diabetic kidney disease.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts Institute of Technology NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-10865338 on NIH RePORTER |
What this research studies
This research focuses on developing new therapies to prevent kidney damage caused by diabetes, a common and serious health issue. The approach involves using lipid nanoparticles to deliver small interfering RNA (siRNA) that can reduce inflammation in the kidneys by targeting specific proteins involved in the disease. By testing these new delivery methods in animal models, the researchers aim to find effective ways to protect kidney function in patients with diabetes. If successful, this could lead to innovative treatments that improve the lives of those affected by diabetic kidney disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with type 1 or type 2 diabetes who are at risk of developing diabetic nephropathy.
Not a fit: Patients who do not have diabetes or those with advanced kidney disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option to halt the progression of kidney disease in diabetic patients.
How similar studies have performed: Previous research has shown promise in using similar siRNA delivery methods for other conditions, indicating potential for success in this novel application.
Where this research is happening
Cambridge, United States
- Massachusetts Institute of Technology — Cambridge, United States (Active)
Researchers
- Principal investigator: Liu, Gary — Massachusetts Institute of Technology
- Study coordinator: Liu, Gary
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.